After Carlsbad, CA-based Verdezyne disclosed last month that it plans to raise more than $15 million in venture funding, I arranged to sit down with Damien Perriman, the company’s vice president of business development.

As it turns out, the startup that was founded in 2005 as CODA Genomics has essentially re-engineered itself over the past 18 months. The company overhauled its core business strategy, recruited a new CEO, E. William Radany, along with a new management team, changed its name, and moved its headquarters from Orange County to Carlsbad, CA, about 28 miles north of San Diego. In changing its name to Verdezyne, the company created an identity that is better aligned with its revised focus on the “green design” of biofuels and industrial chemicals.

The company initially was focused on technology spun out from UC Irvine that used specialized computer algorithms to design synthetic DNA. The company offered its services in Computationally Optimized DNA Assembly, or CODA, to help drug discovery teams at pharmaceutical customers like Eli Lilly and Genentech design synthetic genes that could be used to maximize the production of certain proteins for their biotech drug manufacturing processes.

Perriman, who joined Verdezyne in February, tells me, “Our investors made a decision in 2008 that we could make a lot more money by doing the production ourselves.”

With its extensive experience in computational biology and bioinformatics, Verdezyne saw the value in creating high-diversity libraries of genes, so that various genes could be inserted into fast-dividing yeast cells (and other micro-organisms), essentially programming the microbes to produce enzymes it would not otherwise produce. Verdezyne landed a federal grant last month to help build out its genomic library.

“We prefer to work with yeast,” Perriman says, “but we can work with any fungi or bacterial organism.”

The company, which now has 26 employees, has identified three primary markets for its technology.

The first and most obvious target is an …Next Page »

Comments | Reprints | Share:        

It wasn’t so much the predictions as the discussion that was most interesting at last night’s annual predictions dinner, organized by the Washington Technology Industry Association. Will Twitter be acquired in 2010, and why? Who will have the dominant cloud computing platform in the next couple of years? What kind of startup are you looking to build or finance, and which areas are you staying away from?

A panel of Seattle-area tech entrepreneurs and investors gamely took the bait and had some lively exchanges over the course of an hour. OK, these guys all know each other, and we’ll take what they say with a grain of salt since it’s a public forum—but here were some of the most interesting points they made. (You can read more comprehensive recaps of the panel on Brier Dudley’s blog at the Seattle Times, and soon on TechFlash by moderator John Cook.)

The panel was split 3 to 2, with the narrow majority guessing Twitter will get bought next year. Andy Sack of seed-stage fund Founder’s Co-op predicted Twitter will make more money than Facebook in 2010 (surprising, given the current disparity in the other direction). Glenn Kelman, the CEO of Redfin, an online real estate firm, said Twitter should charge for search (as it has begun to do in partnerships with Google and Bing). Kelly Smith from Curious Office and the startup Pressplane argued that Twitter could be “absorbed by a big company,” but “it’s going to go nowhere.” By the end of the evening, Sack was predicting that Microsoft would buy Twitter next year.

There was a consensus that 2010 could be a big year for acquisitions. Bill Bryant of Draper Fisher Jurvetson boldly predicted that Amazon will buy Netflix, Blockbuster, and Hulu, while opening brick and mortar “Amazon media stores.” Greg Gottesman from Madrona Venture Group said Cisco might buy EMC (for VMware) and Seattle-based F5 Networks, while Microsoft might buy Research In Motion, the maker of the BlackBerry smartphone. Sack predicted Adobe would pick up Seattle photo-editing startup Picnik. Rupert Murdoch (News Corp.) would buy Seattle’s Cheezburger Network, and someone would buy Redfin.

Looking back on 2009 for a minute, the big deals that were questioned by the panel included Adobe’s acquisition of Omniture (Gottesman said it just didn’t make sense strategically) and …Next Page »

Comments (2) | Reprints | Share:        

Aptera, the sleek carmaker backed by Google and Idealabs, didn’t respond to my inquiry earlier this week about reports of an internal split in which founders Steve Fambro and Chris Anthony had left the company. But in an online report published today by The San Diego Union-Tribune, Aptera officials rejected accounts that Fambro and Anthony were ousted in a boardroom showdown.

The company’s status is a keen issue to some 4,000 people, including celebrities Tom Hanks, Robin Williams, and Shaquille O’Neal, who have put down $500 deposits to be the first to buy one of the three-wheel, two-seater vehicles. The Aptera 2e, the company’s first production vehicle, resembles a wingless plane and is expected to cost between $25,000 and $40,000. Aptera is based in Vista, CA, about 30 miles north of San Diego.

Citing a statement issued by Aptera CEO Paul Wilbur, the Union-Tribune says the carmaker had to adjust its production schedule “to align with financing realities.” Instead of producing its first fuel-efficient model in the fall of 2009, as Aptera announced at the beginning of this year, Wilbur says the company will complete its first vehicles in 2010. About 10 of Aptera’s 40 employees have been laid off.

The company, which has raised at least $27.5 million from Google, Idealabs, and other venture investors, is seeking additional funding, according to Popular Mechanics. Aptera says it also intends to resubmit its application for a $75 million loan from the Department of Energy’s Advanced Technology Vehicles Manufacturing Incentives Program.

Aptera says co-founders Fambro and Anthony were not asked to leave. Fambro remains on the board, but has taken a leave of absence from the company until next year. Anthony is now the CEO of Flux Power, a startup in the San Diego area that is developing battery-management systems. In another online account published by Popular Mechanics magazine, Fambro also voiced his continuing support for CEO Wilbur.

Comments (2) | Reprints | Share:        

As startups developing next-generation biofuels emerge in San Diego, Boston, and elsewhere, a business model for rapidly expanding to commercial-scale operations already can be found in the biotech industry, experts said yesterday. The premise of presentations organized by Biocom, San Diego’s life sciences industry group, is that collaborations being formed between biofuel startups and big energy are comparable to the partnerships formed between biotech startups and big pharmaceutical companies.

Biofuels development partnerships will be crucial to meeting renewable fuel standards that the federal government set in the Energy Independence and Security Act of 2007. Wain Fishburn, a founding partner of the Cooley Godward law firm’s San Diego office, said the standards require the U.S. biofuels industry to increase its production fourfold—from 9 billion gallons in 2008 to 36 billion gallons in 2022. Fishburn, who introduced the speakers at the Biocom event, said the ability to meet the federal goal depends on a variety of factors, including the ability to lower the cost of biofuels to be competitive with petroleum-based crude, and the scalability of feedstock, production facilities, distribution, and related infrastructure.

But what it really comes down to, as Verenium (NASDAQ: VRNM) executive William Baum told the audience, is capital.

Baum, who became Cambridge, MA-based Verenium’s executive vice president of business development in 2007 (following the 2006 merger of San Diego’s Diversa and Cambridge’s Celunol) said the need for capital was the theme he heard “over and over again” during a recent meeting that focused on the biofuels industry. “We’ve got hundreds of biofuel companies that are trying to get to the next stage. If you don’t have a big brother with deep pockets, like a BP, Exxon, Shell, or a Chevron, it’s going to be very difficult.”

A number of partnerships already have been established between biofuels startups and major energy conglomerates, Fishburn noted. He listed the following collaborations:

—BP, the London-based global energy conglomerate, has formed two strategic partnerships with Verenium, which has been developing technology to produce cellulosic ethanol using proprietary microbes to accelerate the breakdown of non-edible, high-cellulose plant material into ethanol. Baum described the first collaboration, announced in August 2008, as a technology joint venture for IP. (BP agreed to put up $90 million to develop “low-cost, environmentally sound cellulosic ethanol production facilities in the United States.”) Through a second deal announced nine months ago, BP agreed to provide an additional $45 million and to form a …Next Page »

Comments (4) | Reprints | Share:        

Seattle-based venture capital firm Maveron has been in the news a lot this month. There have been reports about its latest stealth startup, which is a new type of e-commerce play. Another report from VentureWire said Maveron will be selling its shares in Motley Fool—a deal that will generate cash for Maveron, which led a $26.5 million financing of the online investing website in 1999. And then, just yesterday, I got a press release about Maveron expanding to San Francisco and Silicon Valley.

The VC firm, co-founded by Howard Schultz of Starbucks fame, is used to this sort of attention. But the San Francisco news was a bit confusing to me, because Maveron has been active in the Bay Area for a long time. As usual, the interesting stuff is in the follow-up. I had a chance to connect yesterday with Dan Levitan, a fellow co-founder of Maveron and the mastermind of the firm’s consumer-focused investment strategy. Besides the new San Francisco office, I also asked Levitan about the Seattle e-commerce startup his team is currently building; his outlook and themes in the consumer tech space; and his first fateful meeting with Schultz back in the early 1990s.

First, some basic stats. Maveron was founded in 1998 by Levitan and Schultz, and is best known for its early investments in eBay, drugstore.com, Shutterfly, and Cranium. Its current portfolio companies—there are 22 active around the U.S.—include Potbelly Sandwich Works, Pinkberry, LiveMocha, and Altius Education. The venture firm has about $750 million under management.

Levitan explained that opening Maveron’s San Francisco office has been a two-year process, but it doesn’t signify any shift in the firm’s geographic focus. “I don’t see this announcement as anything more than opening an office where we’ve already done business,” he said. “We’re one firm with two offices.”

The San Francisco office is headed by Amy Errett, a veteran of Olivia.com and E*Trade, who was announced as a Maveron partner last year. She is joined by new principal Ben Choi, who was previously with Storm Ventures, In-Q-Tel, and RRE Ventures. As Levitan puts it, instead of Errett flying up to Seattle four times a month, she’ll fly up three times a month (and the Seattle team will fly down the fourth week).

But Levitan emphasized that he’s looking in his own backyard for new investments as much as ever. “Seattle is an economy and region that’s very rich with groundbreaking, innovative consumer companies,” he said, pointing out obvious examples like Starbucks, Nordstrom, Amazon, and Costco. One less obvious company he mentioned was online real estate broker Redfin, which isn’t in …Next Page »

Comments (1) | Reprints | Share:        

Three years have gone by since the region’s top biotech company was taken over by Eli Lilly, so it seemed like a good time to find out where all that talent migrated around the Northwest.

—Icos was once the great hope for Seattle biotech, but now three years have passed since the Bothell, WA-based company agreed to be sold to Eli Lilly for $2.3 billion. I wanted to find out where most of that scientific and business talent went in the wake of the mass layoffs that ensued, so I found a few Icosahedrons (as I’m told some of them like to be called) to help me put together a fascinating list of 270 alumni who have moved on to new opportunities.

—Seattle-based Trubion Pharmaceuticals (NASDAQ: TRBN) said this week that its co-founder and CEO, Peter Thompson, has resigned. He’ll be replaced on a temporary basis by Arch Venture Partners’ Steve Gillis while the company searches for a permanent replacement. I also recapped some of Trubion’s latest tribulations, to give a sense of what Thompson is leaving to his successor.

—Kirkland, WA-based OVP Venture Partners wanted a bigger piece of the original action in San Diego-based Fate Therapeutics, and now it grabbed some of that by leading a $30 million Series B venture round in the stem cell company. Carl Weissman, an OVP managing director and the CEO of Accelerator, will take a seat on Fate’s board as part of the deal.

—Seattle-based Oncothyreon (NASDAQ: ONTY) said it has decided to advance one of its experimental cancer drugs, PX-866, into mid-stage clinical trials next year. This is another sign of the company’s improving financial health, and its shift from cancer vaccines to cancer drugs, which I described in an in-depth feature earlier this year.

—Seattle-based NanoString Technologies earned a golden word of mouth endorsement this week from the Broad Institute of MIT and Harvard, which agreed to buy a couple of NanoString’s gene-expression tools to use them for a three-year research collaboration. Broad director Eric Lander, one of the big names in biology, said NanoString has “exciting” technology.

—People who work in Seattle’s global health cluster love to tell anecdotes about how certain projects can make a difference in people’s lives, but there hasn’t been as much effort to really catalog all the projects going on here and where they extend around the world. That was the goal of the Washington Global Health Alliance, a nonprofit led by Lisa Cohen, who wrote about it in this guest editorial. You can read more about the alliance in a profile I did of Cohen and her fledgling association in January.

Comments (1) | Reprints | Share:        

The threat of global infectious disease was already a significant humanitarian concern when Ken Stuart set up his independent research lab in 1976. Now known as Seattle Biomedical Research Institute, Stuart’s lab directed the research spotlight on tropical diseases, such as malaria, at a time when few others had shown interest.

Fast-forward more than 30 years later: the Seattle region and Washington State have become known throughout the world as a nexus of global health innovation and entrepreneurship.

Original efforts decades ago by SBRI, PATH and the University of Washington have been joined by Fred Hutchinson Cancer Research Center, the Institute for Systems Biology, the Infectious Disease Research Institute, Seattle Children’s Research Institute and its Global Alliance for the Prevention of Prematurity and Stillbirth program, Battelle/Pacific Northwest National Laboratories, Washington State University and, most significantly, the Bill and Melinda Gates Foundation. These groups together now form a regionally based, yet powerful, alliance in the interest of global health. And as a result of their collaboration, this state has become the symbol of the United States’ compassion and goodwill to millions of people whose lives have been improved or saved.

This is not a statement we make lightly. It takes more than personal anecdotes of success to paint an accurate picture. So, we have created a map—a preliminary but precise accounting for the broad and deep impact that our state’s health research organizations have on global disease.

Researchers and health care workers in Washington state directly run 480 health projects in 92 countries, according to a study commissioned by the Washington Global Health Alliance, which examined nine of the state’s global health institutions.

These organizations are responsible for, among others, 183 different projects focusing on emerging and epidemic diseases and 105 vaccine and immunization programs. They work with 593 unique partners, including 44 foreign government entities, 60 corporate partners and 245 hospitals and universities.

To catalyze more effective and successful collaborations, researchers will leverage this study data to increase efficiencies and create new opportunities in their work. Businesses and philanthropists can see the direct impact of their investments and partnerships. Policymakers can use this information to demonstrate the strength of our state’s global health sector in the face of increasing competition. We will make the case for more federal funding and recruiting new global health researchers and organizations to the state, boosting our economy in the process.

This study measured data from all the organizations mentioned above with the exception of the Gates Foundation, which funds projects, but does not implement programs. Not included in those figures are the significant education and training programs spearheaded by our universities and community colleges, other state research organizations and humanitarian and relief organizations, such as World Vision or Mercy Corps. We expect to broaden the scope in future studies mapping global health efforts.

All told, it is clear the magnitude of Washington State’s impact on infectious disease and suffering is significant and exceptional. Ultimately, we hope this study leads to even greater progress toward our common vision-improving health for people regardless of where they may live. You can see the more detailed survey results at www.wghalliance.org.

Comments (1) | Reprints | Share:        

Long before San Diego was known as a hub of telecommunications innovation or for its proliferation of biotech companies, it was a leading center for the development of deep underwater technologies.

During the 1960s and ’70s, scientists from the U.S. Navy laboratories on Point Loma and UCSD’s Scripps Institution of Oceanography founded numerous startups with technologies derived from underwater sensors, acoustics, and signal processing techniques that had been developed for the Navy’s cat-and-mouse games with Soviet submarines. Robotic technology that the Navy had developed to recover a hydrogen bomb from the bottom of the Mediterranean Sea in 1966 led almost directly to the formation of Hydroproducts and Ametek Straza, two companies that made deep ocean ROVs (Remotely Operated Vehicles) in San Diego during the 1970s. Hydroproducts and Ametek Straza faded from San Diego, however, after they were acquired by bigger companies that wanted to introduce ROVs to the offshore oil and gas industry.

It might not be apparent on the surface, but much of that expertise in subsea technologies remains in San Diego today, according to Leonard Pool, who founded Sidus Solutions in 2000 to develop deep underwater pan-and-tilt camera systems and related ROV positioning equipment. Pool, who is moderating a panel discussion today on “marine technology as an important growth industry” for San Diego, says close to 150 companies continue to ply their trade here.

Alvin Diving off California

“When the U.S. Navy decided that San Diego was going to be a port for submarines, all these companies sprang up,” Pool tells me. “We do get looked at as a cottage industry.” He says these companies have thrived, despite a post-Cold War decline in defense funding for new submarine-hunting technologies. One likely reason, Pool says, is that the “oil and gas community continues to look at San Diego as a hub for subsea technology development.”

Pool’s panel discussion is part of “The Maritime Collaboration Summit,” a two-day conference organized by the Maritime Alliance, a San Diego non-profit industry group, aboard the tourism ship Inspiration Hornblower. The summit, which ends today, is intended to increase awareness of San Diego’s importance as a hub for technology innovation, and to encourage collaboration between the scientific community and commercial maritime innovators, according to Michael B. Jones, president of the Maritime Alliance.

“Right now, the maritime community in San Diego is very fragmented with little visibility or public understanding of its importance,” says Jones, who also heads …Next Page »

Comments | Reprints | Share:        

GenVault wants to bring biological samples in from the cold. For decades, the biological samples used to diagnose or study disease have been stored in freezers, which use a lot of electricity. GenVault markets dry-storage technologies that allow scientists to store samples—such as DNA from a blood test—at room temperature.

GenVault CEO David Wellis argues the company’s technologies free up lab space and are better for the environment. He says that one of GenVault’s desktop storage units can hold as many samples as an average-size lab freezer, which has the same carbon footprint as five automobiles. Freezers have another major drawback: a single power failure can destroy years of work.

Wellis says the time is right for his company. The use of genomic analysis for disease diagnosis, scientific research, and forensic criminal investigations is exploding, thanks in part to technical advances that enable the swift decoding of genes. All these genetic tests start with biological samples, such as blood, urine, or spit. The RAND Corp. recently estimated that more than 307 million tissue specimens are stored in the United States, with more than 20 million specimens added each year. That means more and more freezers are taking up lab space, and running up electricity bills.

GenVault, which is based about 26 miles north of San Diego, in Carlsbad, CA, estimates that sample transport and storage represents a $4.5 billion business opportunity. It is also an area in which innovation has been lacking. “All the technical development has occurred in sequencing and informatics,” says Wellis. “The management of samples has seen no innovation. It is a gaping hole.”

GenVault got started in late 2001 to fill that perceived hole. The venture-backed company has raised more than $32 million to date, and has numerous customers, including the national Centers for Disease Control and Prevention, Genome Québec, and Amgen. The company expects to soon announce a new diagnostic lab customer that expects to store 750,000 samples using GenVault’s technology. Wellis says GenVault, which has 40 employees, could breakeven by the end of next year.

The company markets two products. One is a chemically treated paper that preserves bits of whole samples, such as blood or spit; the other a salt-like mineral matrix that preserves purified DNA. Here is how GenVault says …Next Page »

Comments | Reprints | Share:        

[Update: 12:30 pm Pacific, 11/20/09] Icos was once the great hope for Seattle biotech. Founded in 1990 with an investment from Bill Gates, it went on over the next 15 years to create a $1 billion molecule for treating erectile dysfunction, and employed about 700 people nationwide at its peak. For a while, it looked like it would carry the torch as the only big, independent, profitable biotech company with growth potential and staying power in the Seattle area.

That hope was dashed about three years ago, when Icos agreed to be acquired by its partner, Eli Lilly, ultimately for about $2.3 billion. Many readers will remember the controversy over this deal, which I covered with intensity through the fall of 2006 for The Seattle Times. Employees who had worked together for years and built a great camaraderie were deeply upset with CEO Paul Clark, who enriched himself with a $23 million golden parachute through the transaction while kicking most of them to the unemployment line. Shareholders objected to what they saw as a sweetheart deal for management, and ultimately forced Lilly to raise its bid before they handed over their shares.

Even Icos’s founding CEO and legendary leader, George Rathmann, who was not in good health at the time, objected to what had become of the company he created. It had essentially squandered an entire pipeline of drug candidates in the wake of its hit with tadalafil (Cialis), leaving no real opportunity for an encore, and no real strategic alternatives other than getting bought by Lilly.

About 550 people were employed locally at Icos at the time the Lilly acquisition closed in January 2007, and about 350 high-paying local jobs were cut. All that was left was a contract biotech drug manufacturing facility, which Lilly didn’t want, and sold to CMC, a Danish company that continues to operate at the old Icos facility in Bothell today.

But now that three years have gone by, what happened to all that intellectual capital that came to create exciting new biotech drugs for Icos? This is an important question for the future of Seattle biotech, given how companies that look to start or expand to new locations always consider the caliber of the local workforce as one of the main criteria.

From what I’ve been able to gather by talking to some very helpful former Icosians, I’ve discovered that quite a few of these bright people have stayed in the Seattle region. Some left for new opportunities elsewhere, usually after they couldn’t find suitable work in Seattle. Quite a few more than I expected have gone on to co-found or play critical technical roles in some intriguing startups—including Calistoga Pharmaceuticals, CoCrystal Discovery, Mirina, Theraclone Sciences, and Xori.

What follows here is a list of more than 270 names I’ve been able to gather from people who had made contributions to the science, medical, or business aspects of Icos. Special thanks go out to the following Icos alumni who were hugely helpful in allowing me to piece this list together: David Crowe of Mirina; Pat Gray of Accelerator; Ed Kesicki, Allen Casey, and Stephanie Florio of the Infectious Disease Research Institute; and Albert Yu of Calistoga Pharmaceuticals.

Of course, this list isn’t comprehensive. I’ve done my best to verify everybody’s connection to Icos through their LinkedIn profiles or from other sites—but I haven’t been able to confirm every name referred to me. Some people haven’t kept their profiles up to date on LinkedIn or on other sources. So if you can think of former Icos alumni who I’ve overlooked, or if you see any mistakes, please send us an e-mail at editors@xconomy.com, or to me personally at ltimmerman@xconomy.com. Or feel free to post a comment at the bottom of the story. I figure this is a starting point for what could be a valuable networking resource.

—Lee Adams, research scientist, Institute for Systems Biology

—Janet Adolphson, senior research scientist, AMRI

—Laura Afflerbaugh, research associate, Genentech

—Brian Albarran, senior scientist, Trubion Pharmaceuticals

—Lynn Allen, founder, Allen Clinical Research

—Dan Allison, senior director of therapeutic design, VLST

—Juli Ashburn, senior field force automation administrator, ZymoGenetics

—Eric Austin, senior toxicology consultant, Veritox

—Connie Ave-Teel, manager, lab support, CMC Icos

—Tim Axtelle, vice president of product development, Allozyne

—Susan Aznoff, owner, Petlane Pals

—Lauret Ballsun, owner, LBC Pharmaceutical Professionals

—Cari Barthe, recruiting project manager, NWRPros

—Ted Baughman, senior scientist, chemistry, Saltigo

—Chan Beals, senior director, Merck

—Kelly Bickley, quality control associate scientist, CMC Icos

—Julie Birashk, process development associate, CMC Icos

—Bodil Bjorner, development associate, CMC Icos

—Kyla Bjornson, senior research associate, Gilead Sciences

—Kim Black-Washington, director of marketing and strategic development, Xcelience

—Leonard Blum, senior vice president and chief commercial officer, Theravance …Next Page »

Comments (2) | Reprints | Share:        

San Diego’s NextImage Medical, Inc., which has developed a Web-based system for scheduling and managing diagnostic imaging services, says it has raised $5 million in Series A funding in a round led by Chrysalis Ventures of Louisville, KY. Liz Griggs founded NextImage Medical last year as a way to provide high-quality, low-cost radiology services, either through insurers, self-insured employers, or direct-to-consumer. A statement from NextImage Medical says Griggs previously was the founder of New Jersey-based One Call Medical, a radiology preferred provider organization (PPO) that was sold in 2003 for $115 million.

Comments | Reprints | Share:        

I had an opportunity to sit down recently (along with several other journalists) for an informal chat with Ellen Pao, a partner at Kleiner Perkins Caufield & Byers and a member of the famed Menlo Park, CA, venture firm’s GreenTech investment team.

Pao was in town to be the keynote speaker at the inaugural Cleantech San Diego Showcase, an event the non-profit industry group intends to hold four times a year as a way of calling attention to emerging green technologies and the local companies developing them. Pao provided an overview of KPCB’s GreenTech team, which consists of 20 partners in the United States and China. The firm has invested about $680 million over the past five years in nearly 50 startup companies, most of which remain in stealth mode.

Pao was gracious, but not especially forthcoming. For example, she told us that KPCB’s greentech investments include funding San Diego-based V-Vehicle Co., which announced plans earlier this year to build a new line of “environmentally friendly and fuel-efficient” cars in Northeastern Louisiana. The green aspect of the V-Vehicle’s design apparently figures in the startup’s request for a $250 million low-interest loan under the Department of Energy’s Advanced Technology Vehicle Manufacturing program. But V-Vehicle has not explained publicly how or why its car is eco-friendly, which has led to conflicting media reports (with some describing it as an electric vehicle). But Pao declined to explain why V-Vehicle is green, saying KPCB doesn’t talk about portfolio companies that are still in stealth mode—even though partners John Doerr and Ray Lane participated in a news conference that Gov. Bobby Jindal of Louisiana held in June to announce the state’s support for the project.

Pao said KPCB’s cleantech investments are divided among startups that are focused in a variety of green categories, including energy efficiency, cars and transportation, batteries (especially companies developing new energy storage capabilities for electric utilities), renewable energy, and “carbon management and sequestration,” i.e., technologies for preventing carbon dioxide from wafting into the atmosphere by capturing the gas and piping it underground.

“There’s a lot of passion around trying to solve the global warming problem,” Pao said. “We’re looking, though, for big solutions. We have some projects, and we think it’s a big opportunity once there is a price on carbon.” She was referring to a “cap and trade” proposal put forward by the Obama Administration that would set strict limits on pollution that causes …Next Page »

Comments (1) | Reprints | Share:        

[Updated 11/16/09 6pm. See below] Microsoft co-founder and renowned technologist Paul Allen has been diagnosed with non-Hodgkin’s lymphoma, a form of cancer, as of early this month, according to an e-mail message sent from Allen’s sister, Jody Allen Patton, to employees of Seattle-based Vulcan and its affiliates this afternoon. The message was sent to Xconomy and other media outlets by a Vulcan spokesperson.

Doctors say Allen has diffuse large B-cell lymphoma, which is a relatively common form of lymphoma, and he has begun chemotherapy, according to the e-mail. The message pointed out that Allen “beat Hodgkin’s a little more than 25 years ago and he is optimistic he can beat this, too.” That form of cancer is different from Allen’s current diagnosis, which is classified as a non-Hodgkin’s lymphoma.

Non-Hodgkin’s lymphoma is an umbrella term for cancers in which white blood cells of the immune system start growing out of control, according to the National Cancer Institute. The disease is the fourth most commonly diagnosed cancer in the U.S. each year, following lung, bladder, and melanoma tumors, according to the American Cancer Society. About 66,000 new cases are expected to be diagnosed this year in the U.S., and about 19,500 people are expected to die from the disease. Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin’s lymphoma, accounting for 30 percent of all newly diagnosed cases, according to an expert review published by the Lymphoma Research Foundation.

Vulcan spokesman David Postman wouldn’t comment on any specific questions about the stage of Allen’s disease, how early it was detected, whether it is an aggressive or slow-growing form of lymphoma, or where he is getting treatment.

Those questions are key to determining what kind of prognosis Allen has. His form of cancer is generally considered an aggressive, fast-growing lymphoma and requires immediate treatment, according to the Lymphoma Research Foundation’s description, authored by Carol Portlock of Memorial Sloan-Kettering Cancer Center in New York, Julie Vose of the University of Nebraska Medical Center in Omaha, NE, and Bruce Cheson of Georgetown University Hospital in Washington D.C. The first sign is usually when the lymph nodes swell in the neck, armpit, or groin—other symptoms include night sweats, unexplained fevers, and weight loss, according to the summary from Portlock and colleagues.

A common treatment for the disease is a regimen of chemotherapy combined with Roche and Biogen’s targeted antibody drug rituximab (Rituxan), which kills excess B-cells of the immune system. The combination treatment can lead to a cure in a large number of patients. “Even when a cure is not possible, treatment can often keep the disease away for many years,” Portlock wrote.

“Paul is feeling OK and remains upbeat,” the Vulcan message stated. “He continues to work and he has no plans to change his role at Vulcan. His health comes first, though, and we’ll be sure that nothing intrudes on that.”

Here is the Vulcan e-mail in its entirety [added 11/16/09 6pm]:

.

To employees of Vulcan and affiliates:

I want to let you know that Paul was recently diagnosed with non-Hodgkin’s lymphoma.

He received the diagnosis early this month and has begun chemotherapy. Doctors say he has diffuse large B-cell lymphoma, a relatively common form of lymphoma.

This is tough news for Paul and the family. But for those who know Paul’s story, you know he beat Hodgkin’s a little more than 25 years ago and he is optimistic he can beat this, too.

Paul is feeling OK and remains upbeat. He continues to work and he has no plans to change his role at Vulcan. His health comes first, though, and we’ll be sure that nothing intrudes on that.

We would ask you to respect Paul’s privacy and not discuss this outside of the office.

If you have any questions, please ask your EC member.

Thank you in advance for what I know will be all your good thoughts for Paul.
Jody

.

Comments (1) | Reprints | Share:        

[Updated: 5:55 pm Pacific, 11/16/09] Trubion Pharmaceuticals, the Seattle-based company developing new drugs for autoimmune diseases and cancer, said today that its founding CEO, Peter Thompson, has resigned and director Steve Gillis of Arch Venture Partners will step in to fill the void as executive chairman.

Trubion (NASDAQ: TRBN) said today that Thompson is leaving his positions as chairman, CEO and president of the company to “pursue other interests,” and Gillis, a member of the board, has stepped up to serve as acting president and executive chairman of the company while it plans to start a formal search for a new CEO. The company has also shuffled a few other management slots, with Michelle Burris being promoted from chief financial officer to chief operating officer, and John Bencich, the company’s senior director of finance, receiving a promotion to take Burris’s place as CFO.

The company has struggled the past two years, since it underwhelmed investors with results from a 276-patient clinical trial of its lead drug candidate, TRU-015 for rheumatoid arthritis. Back in February, the company cut one-fourth of its workforce in an effort to hold onto its remaining cash. But the company has gotten a little bit of mojo back in recent months. It announced encouraging results from a second drug candidate, TRU-016, for leukemia in June, and parlayed that into a partnership with Redwood City, CA-based Facet Biotech (NASDAQ: FACT) that generated $20 million in upfront cash, and could be worth as much as $176 million over time. The company still has a partnership intact with Pfizer to develop the rheumatoid arthritis drug, which it inherited through its acquisition of Wyeth.

Today’s statement from Trubion didn’t say why Thompson is leaving, or what he plans to do in the future, other than that he’ll be available as a consultant to the company. He was listed as 49 years old when the company issued its latest proxy statement in April. Thompson didn’t respond immediately to a request for comment, but noted in a statement that, the company has two partnerships, and three drugs in clinical trials. “With these foundational strengths, a talented leadership team, and an upcoming year replete with significant milestones from its clinical programs, Trubion is well-positioned to realize its potential,” Thompson said in the statement. “I have great confidence in the continued ability of the Trubion team to execute its strategy.”

While Trubion conducts its search for a new CEO, Burris said the company will continue to work on executing goals within its partnerships with Pfizer and Facet Biotech.

“Peter set the company up very well,” Burris says. “We’re well positioned, and we’ll continue to execute on our programs.”

Trubion went public three years ago on enthusiasm for TRU-015, a product designed by Trubion scientists to have the same targeting capability of Roche and Biogen Idec’s rituximab (Rituxan) against inflammatory cells with a marker called CD20. But because the Trubion drug is a smaller molecule than Rituxan, it should be better at penetrating deep into tissues like bone marrow and lymph nodes, where it can stop overactive immune system B-cells from causing damage. Ed Clark of the University of Washington, an immunologist and scientific adviser to the company, once called these “leaner and meaner” drugs.

Thompson, along with Jeff Ledbetter and Ken Mohler, co-founded Trubion in November 2002, when it was originally called Genecraft. Arch Venture Partners, Frazier Healthcare Ventures, Oxford Bioscience Partners, ATP Capital, and Bill Gates’ Cascade Investment all participated in a $13.6 million financing at that time. Mohler said the founders had “a shared vision of the next great immunology company in Seattle” like Immunex once was.

But Trubion has struggled to gain momentum with investors as a public company. It went public at $13 a share, and closed today at $4.13.

[Update: 5:55 pm Pacific time, 11/16/09.] Trubion disclosed Thompson’s severance package later today in a regulatory filing. He will receive one year of base pay, about $416,000, on the payroll date in January, and a lump-sum payment of about $28,000 for unused vacation time. He agreed to provide one year of consulting services, for no more than 20 hours a week, and will get paid $25,000 per month for the consulting, the company said. Thompson’s unvested stock options will immediately vest, giving him the right to buy 59,820 shares of Trubion stock, according to the document.

Comments | Reprints | Share:        

Paul Wilbur, a Detroit auto industry veteran who was named CEO of Carlsbad, CA-based Aptera 14 months ago, gave no indication of internal turmoil at the futuristic car’s headquarters when he appeared last week at an event sponsored by Cleantech San Diego.

But as Darryl Siry reports today on Wired’s Autotopia blog, a prolonged power struggle that pitted Aptera founders Steve Fambro and Chris Anthony against Wilbur and Aptera board members apparently came to a head in recent weeks. Wired says rumors about the founders’ departure, as well as layoffs amid financial difficulties, began appearing last week on the Aptera Forum, an online message board for Aptera car enthusiasts. Aptera did not immediately respond to an e-mail query seeking the company’s response to the reports. According to Wired, the company says it’s slowing down its burn rate while waiting for the Department of Energy to review its loan application, and maintains that its relationship with Fambro and Anthony remains positive.

Fambro, who founded Aptera about six years ago, has previously said his aim with the company was to build a safe and comfortable passenger vehicle that was more fuel-efficient than anything else on the road. The company says the prototype of its aerodynamic pod-shaped, three-wheel vehicle gets 230 miles to the gallon.

Aptera raised about $24 million roughly 18 months ago from investors that include Google and Idealab. CEO Wilbur told me last year that the company was having no trouble attracting additional funding, but the Wired blog reports that additional funding has in fact been difficult to secure during a drawn-out battle over which course the company should be steering.

Comments | Reprints | Share:        

San Diego’s Global Analytics Holdings says it has raised $10 million of a targeted $14 million round that consists of equity investments, options, and rights to securities, according to a recent regulatory filing. The company provides consulting services for business customers and specializes in developing software for statistical analysis, predictive modeling, and neural networks.

The filing indicates the capital is being raised in connection with a merger, acquisition, or exchange offer, but founding CEO Krishna Gopinathan did not respond to a call or e-mail seeking further information. According to the Global Analytics website, Gopinathan was the primary inventor of Falcon Fraud Manager, a neural-network technology developed at San Diego-based HNC Software (now part of Fair Isaac) that is used to protect most credit cards worldwide.

Global Analytics has been operating at least five years and has more than 100 employees, according to its website. A number of key executives at Global Analytics, including the executive vice president of analytics, vice president of products, and vice president of software development, are former HNC employees.

Last year, Global Analytics named Larry Rosenberger, the former CEO of Minneapolis, MN-based Fair Isaac, to its board of directors. The company also noted that Rosenberger and his wife Diane invested in the San Diego startup. Peter Rip, a general partner at San Francisco’s Crosslink Capital, also is on Global Analytics’ board, although Crosslink does not identify Global Analytics as a portfolio company.

Global Analytics also has formed a strategic partnership with Hewitt Associates, the Illinois-based human resources and outsourcing firm, and has been working on what it calls “the objective quantification of the value of human capital investments.” The company says it has been working with Hewitt in recent years to pioneer development of comprehensive models that tie such human resources metrics as talent attraction, retention, and engagement to shareholder value, creating what Hewitt calls its Human Capital Foresight.

Comments | Reprints | Share:        

It turns out that Don Dodge—famous among entrepreneurs for putting a personal face on Microsoft’s operations in New England, until his unceremonious termination earlier this month—was only in job limbo for about about an hour and a half. Dodge sends Xconomy word this morning that he has been hired by Microsoft archrival Google.

Vic Gundotra, Google’s vice president of engineering, was the first person to contact him with a job offer, “90 minutes after the news of the layoff hit” on November 4, Dodge says in a blog post about his move.

At Microsoft, Dodge was director of business development for the Emerging Business Team. In an e-mail, Dodge says he’ll have a similar role at Google: “My main job will be working with developers helping them build apps on Google technologies and platforms. Startups will always be my first love, so I will spend as much time as possible with developers at startups.”

Dodge says he will spend his “20 percent time”—the one day per week that Google employees are encouraged to spend on personal projects—working with Google Ventures, the venture funding wing led by Rich Miner from Google’s Cambridge office and Bill Maris from the company’s Mountain View, CA, headquarters. “There are some obvious synergies there,” Dodge writes.

Dodge’s job shift will ultimately take him away from Massachusetts. But he says he’ll be working from Google’s Cambridge office through the holidays, and that he will be “back in Boston so often people will think I still live here. It was the same after I left Silicon Valley…they think I still live there.”

Michael Arrington of TechCrunch broke the story about Dodge’s new job last night, and Dodge himself shared more details about it this morning.

In previous public statements about his departure from Microsoft, Dodge has been diplomatic to the point of saintliness. But in today’s post he takes the gloves partway off, writing that “laying off 5,000 people when you have $37B in cash and huge profits is not cool.”

He also takes a few jabs at Microsoft products—calling Microsoft’s Outlook e-mail management program “tired,” saying that his Windows Mobile 6.5 smartphone “didn’t measure up,” and commenting that Microsoft’s Internet Explorer browser is too slow. At Google, naturally enough, Dodge will be using Gmail to manage his e-mail, getting an Android-powered mobile phone, and using the Google Chrome browser. And it’s probably safe to assume he won’t be doing many searches on Bing.

Comments (2) | Reprints | Share:        

San Diego serial entrepreneur Michael Robertson is going to have to find something else to do now that Gizmo5, the VoIP (voice-over-Internet-protocol) company he founded in 2003, has become part of a certain search giant to the north. We have that news and more.

—Google confirmed that it’s buying San Diego-based Gizmo5, a six-year-old company that provides Internet-based calling software for mobile phones and computers. The service will become part of the Google Voice number-unification service. Google did not disclose the purchase price, which media reports put at about $30 million. Gizmo5’s 6 million users will still be able to use the service, according to a statement. But Google is suspending new Gizmo5 signups, and existing users can no longer sign up for a call-in number.

—Platformic, a Web-based startup that enables customers to create and manage their own websites, said it is adding social media capabilities. The two-year-old San Diego-based company, which has targeted broadcast companies, says its expanded software-as-a-service product will help a broadcaster’s audience share photos, create their own user profiles, and create personal blogs on the broadcaster’s Platformic-powered website.

—Qualcomm’s No. 2 executive opened a regional mobile technology conference in San Diego by providing an overview of steps the chipmaking giant is taking to help ease the pressure on wireless network bottlenecks as mobile data traffic soars. Qualcomm (NASDAQ: QCOM) Chief Operating Officer Len Lauer told the 3G CDMA Americas Regional Conference that in the year 2014, worldwide mobile data traffic in one month will exceed mobile data traffic for all of 2008.

—Technology innovations that help companies optimize their profitability will likely lead to the next wave of analytics-based software startups, according to Stephen Coggeshall of San Diego-based ID Analytics. Another hot area will be analytics that can help forecast consumer behavior, said Coggeshall, who was participating in a discussion about new opportunities in analytics during the San Diego Software Industry Council’s annual forum on analytics.

—Israel’s Panoramic Power won $250,000 and became the first winner of the top QPrize, the incentive prize competition launched earlier this year by Qualcomm Ventures. Panoramic Power is developing energy-monitoring wireless technology that enables a company or institution to deploy so-called “smart grid” technologies within their existing facilities.

—The San Diego-based Cannon Power Group said is getting $19.4 million in federal renewable energy grants to help fund construction of a giant wind farm in eastern Washington state, about 110 miles east of Portland, OR. The $1 billion Windy Point/Windy Flats project is expected to generate enough electricity for 250,000 homes.

Comments | Reprints | Share:        

Robots have already found limited work in healthcare by assisting surgeons with operations and physical therapists with rehabilitating patients, among other jobs. So why can’t robots keep an eye on seniors and give them their medications?

Bedford, MA-based iRobot (NASDAQ:IRBT) made headlines last month with the announcement of its recently created healthcare division, which is being headed by veteran software entrepreneur Tod Loofbourrow. The company’s ambitious plan is to develop a robot to help seniors live independently in their homes—something that no other company has accomplished. To learn more, I headed over to the firm’s headquarters last week.

The 7-year-old in me hoped to show up at iRobot and find the “medical droid” from Star Wars. But I knew not to expect to see such a humanoid robot, so I wasn’t disappointed when Loofbourrow told me that there were no healthcare robots to show me. Yet at one point during our interview, he flipped open his laptop and showed me a conceptual video of one of the company’s robots rolling over to an elderly person’s bedside and placing a bottle of pills on a side table. He said the video was intended to illustrate the company’s long-term vision for a healthcare robot, but the robot depicted was not a prototype of what the firm plans to market initially.

The senior citizen in the video, however, represented the first demographic iRobot aims to serve with a healthcare robot. There could be tremendous value in a robot that could help seniors live at home and avoid nursing homes, Loofbourrow explained, noting that the average nursing home in Massachusetts costs about $10,000 a month. Supporting patient care in the home may also help seniors avoid costly hospitalizations, which are a major factor in the whopping $2.4 trillion annual healthcare bill in the U.S. But the U.S. healthcare system hasn’t fully embraced using telemedicine—let alone robots—to enable patients to receive care in their homes.

Nevertheless, the leadership of iRobot decided that the time is right to launch a healthcare division, Loofbourrow said. The company has been interested in how its robots could be used to help patients for more than a decade. Indeed, company chairman and CEO Colin Angle told me back in 2006 that a robot for home healthcare was about three years from the market. And two years ago I spotted a concept robot the company developed called “CiCi” at a medical technology conference; an MIT robotics engineer told me for this Mass High Tech story that the stationary robot had two-way audio and remote-monitoring capabilities. Healthcare could eventually become a major business for iRobot, which already has succeeded in introducing robots like the Roomba for the household market and the PackBot for the military market.

“The company sees an opportunity to really transform a market,” Loofbourrow said. “So I’m here to build a very big business and a third leg of the stool for iRobot.”

Loofbourrow’s fascination with robotics dates back at least as far as his teenage years. As the Boston Globe’s Scott Kirsner reported in his blog post last month, Loofbourrow was16 years old when he wrote a book called “How to Build a Computer-Controlled Robot” in the late-1970s. He explained that when he was a child, his father was an engineer at Bell Labs and their basement was filled with circuit boards and other parts for building robots. The robot he built around a single-board microprocessor featured voice recognition and ultrasonic navigation, he said.

The Harvard University graduate was most recently founder and CEO of Waltham, MA-based Authoria, a provider of talent management software that Loofbourrow grew into a $40 million annual business with more than 300 employees in the U.S., Europe, and India. He sold the company in 2008 to White Plains, NY-based Bedford Funding for …Next Page »

Comments (2) | Reprints | Share:        

We’ve all been wondering how the Adobe layoffs, reported earlier this week, may affect the Seattle area—especially given the slew of other recent cutbacks in the local tech industry. Adobe (NASDAQ: ADBE), which is headquartered in San Jose, CA, has a strong presence in Seattle. As of recently, it employed some 500 people, focused on product development, operations, and advanced technology and research, at its Fremont offices.

Well, one prominent executive who’s leaving the company locally is Bill McCoy, Adobe’s general manager of ePublishing Business. McCoy is Adobe’s main e-book person. He made key contributions to Adobe’s PostScript and PDF technologies, and his team has helped lead projects like Adobe Reader Mobile SDK, Adobe Content Server, Adobe Digital Editions, and Adobe InDesign. He’s on the board of the International Digital Publishing Forum, and has been heavily involved in the EPUB standards movement. (You can read more about McCoy at TeleRead.org.)

In a blog post this week, McCoy said he’s leaving Adobe “in the near future” to pursue other opportunities yet to be determined. “I will be taking a little bit of time off, but there is no doubt that I’ll continue to be involved in the future of digital books, especially where that future intersects with web standards and open source,” McCoy writes. “I believe that Adobe will continue to play a critical role as an enabler of interoperable solutions, but I also believe that the community needs to stay vigilant to ensure that for-profit corporations don’t just talk the talk about being open, but also walk the walk.”

It sounds like Adobe is overhauling its efforts in the area, as its competition with Amazon and other e-publishing companies heats up. In a blog post, Adobe said it “has made the decision to expand its investment in digital publishing, creating a new organization focused on delivering products to increase digital revenue opportunities for book, newspaper and magazine publishers. This organization will combine the efforts of Adobe’s eBook business responsible for the Adobe Reader Mobile SDK, Adobe Content Server, Adobe Digital Editions, and PDF and EPUB authoring support in Adobe InDesign with Adobe’s digital newspaper and magazine efforts.” The company added, “We are particularly excited about what we have in store for 2010. We plan to further our reach to emerging mobile reading platforms to allow readers to read anywhere, on any device.”

Comments (1) | Reprints | Share: